Medtronic (NYSE:MDT) Shares Sold Rep. Richard McCormick

Key Points

• Rep. Richard McCormick sold $1,001–$15,000 of Medtronic shares on July 30 from his Growth Partners Roth IRA, alongside similarly sized sales in nine other companies, including McDonald’s, PepsiCo and Johnson & Johnson.
• Medtronic opened at $90.44, with a market capitalization of $115.77 billion and a 12-month trading range of $73.31–$106.33. The company recently beat quarterly revenue and earnings expectations, reporting $9.81 billion in revenue and $1.55 in adjusted EPS.
• Medtronic increased its quarterly dividend to $0.72 per share, implying a 3.2% annualized yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $98.83, while institutional investors own 82.06% of the stock.

Representative Richard McCormick (Republican-Georgia) recently sold shares of Medtronic PLC NYSE: MDT. In a filing disclosed on August 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Medtronic stock on July 30th. The trade occurred in the Representative's "GROWTH PARTNERS ROTH IRA" account.

Representative Richard McCormick also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of McDonald's NYSE: MCD on 7/30/2026.
• Sold $1,001 - $15,000 in shares of NextEra Energy NYSE: NEE on 7/30/2026.
• Sold $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 7/30/2026.
• Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 7/30/2026.
• Sold $1,001 - $15,000 in shares of L3Harris Technologies NYSE: LHX on 7/30/2026.
• Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 7/30/2026.
• Sold $1,001 - $15,000 in shares of Intercontinental Exchange NYSE: ICE on 7/30/2026.
• Sold $1,001 - $15,000 in shares of Illinois Tool Works NYSE: ITW on 7/30/2026.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 7/30/2026.
• Sold $1,001 - $15,000 in shares of Emerson Electric NYSE: EMR on 7/30/2026.

Medtronic Stock Performance

MDT stock opened at $90.44 on Tuesday. The stock has a market capitalization of $115.77 billion, a PE ratio of 24.25, a price-to-earnings-growth ratio of 2.45 and a beta of 0.55. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. The stock's 50 day simple moving average is $83.40 and its 200 day simple moving average is $86.19.

Medtronic (NYSE:MDT - Get Free Report) last issued its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The business had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. During the same period last year, the business posted $1.62 EPS. The company's revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were given a $0.72 dividend. This is a boost from Medtronic's previous quarterly dividend of $0.71. The ex-dividend date of this dividend was Friday, June 26th. This represents a $2.88 annualized dividend and a yield of 3.2%. Medtronic's payout ratio is currently 77.21%.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 4,189 shares of Medtronic stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares in the company, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.26% of the company's stock.

Institutional Trading of Medtronic

Several large investors have recently added to or reduced their stakes in MDT. Anfield Capital Management LLC boosted its stake in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company's stock worth $27,000 after acquiring an additional 230 shares during the last quarter. Monetary Solutions Ltd purchased a new stake in shares of Medtronic in the 4th quarter worth $27,000. Acumen Wealth Advisors LLC purchased a new stake in shares of Medtronic in the 4th quarter worth $29,000. IAG Wealth Partners LLC bought a new position in Medtronic in the 2nd quarter worth $30,000. Finally, Imprint Wealth LLC bought a new position in Medtronic in the 3rd quarter worth $31,000. 82.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

MDT has been the topic of several recent analyst reports. Evercore set a $105.00 price objective on Medtronic in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft decreased their target price on Medtronic from $100.00 to $78.00 and set a "hold" rating for the company in a research report on Thursday, June 4th. Sanford C. Bernstein lowered their target price on shares of Medtronic from $112.00 to $97.00 and set an "outperform" rating on the stock in a research note on Thursday, June 4th. Weiss Ratings downgraded shares of Medtronic from a "hold (c+)" rating to a "hold (c)" rating in a report on Thursday, May 21st. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $118.00 price target on shares of Medtronic in a research note on Thursday, June 4th. Eighteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Medtronic has an average rating of "Moderate Buy" and a consensus price target of $98.83.

About Representative McCormick

Rich McCormick (Republican Party) is a member of the U.S. House, representing Georgia's 7th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. McCormick (Republican Party) is running for re-election to the U.S. House to represent Georgia's 7th Congressional District. He declared candidacy for the 2026 election. Rich McCormick lives in Suwanee, Georgia. McCormick served in the U.S. Marine Corps and the U.S. Navy. He earned an M.B.A. from National University and an M.D. from Morehouse School of Medicine. McCormick's career experience includes working as an emergency medicine physician with Gwinnett Medical Center and Northside Hospital, a Marine officer instructor with Georgia Tech and Morehouse College, and a pilot.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source